期刊文献+

PLGA微球的修饰及其应用 被引量:8

Decoration and Application of PLGA Microspheres
原文传递
导出
摘要 微球作为新型的药物载体系统已广泛用于临床研究,高分子化合物材料聚乳酸-羟基乙酸(pdy lactic-co-glycolic acid,PLGA)因其良好的生物相容性和生物可降解性备受关注。近年来,PLGA微球的研究一直是热门,针对其释放缺陷出现了很多复合修饰方法,主要包括环糊精、壳聚糖、聚乳酸、明胶、泊洛沙姆、聚乙烯亚胺等高分子材料的联用、针对末端基团进行化学修饰以及制备成核壳型微球,在保证包封率的情况下大大降低突释,改善药物释放曲线,从而在药物传递、基因治疗、影像诊断、组织工程等领域得到了广泛的应用。 Microspheres as novel drug delivery carriers have been widely used in clinical study, and poly lactic-co-glycolic acid(PLGA) has been one of the most attractive polymeric candidates used to fabricate devices for drug delivery due to the biocompatible and biodegradable characteristics. In recent years, in order to figure out the defects during the drug release, polymeric combination and chemical modification has been extensively studied. And the design of double-walled microspheres also has been investigated. Moreover, encapsulation efficiency and the release profiles can be improved by different modification methods. And it is extensively used in drug deliver, gene therapy and imaging diagnosis, especially in the fields of tissue engineering.
出处 《中国现代应用药学》 CAS CSCD 2016年第6期830-836,共7页 Chinese Journal of Modern Applied Pharmacy
基金 国家自然科学基金(81173000) 浙江省自然科学基金(LY14H300005)
关键词 聚乳酸-羟基乙酸 微球 修饰 应用 PLGA microspheres decoration application
  • 相关文献

参考文献5

二级参考文献62

  • 1陈立娟,郭家彬,彭双清.阿霉素致大鼠心脏氧化损伤及其机制的研究[J].毒理学杂志,2006,20(3):147-149. 被引量:22
  • 2文柳静.多柔比星心脏毒性的研究[J].中国药师,2006,9(10):956-958. 被引量:7
  • 3卢亚欣,何海冰,崔越,唐星.乙酸异丁酸蔗糖酯原位凝胶流变学性质的研究[J].药学学报,2007,42(4):445-449. 被引量:7
  • 4Bertani T, Poggi A, Pozzoni R, et al. Adriamycin-induced nephritic syndrome in rats[J]. Laboratory Investigation,1982,46(1): 16-23.
  • 5Ma P X. Biomimetic materials for tissue engineering [J]. Advanced Drug Delivery Reviews, 2008, 60(2):184-198.
  • 6Jeon O, Lira H W, Song S J,Lee M,Kim B S. Poly(L-lactide-co-glycolide) nanospheres conjugated with a nuclear localization signal for delivery of plasmid DNA[J]. Journal of Drug Target,2007,15: 190-198.
  • 7MOLLER HJ, LLORCA PM, SACCHETTI E,et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies [ J ]. Int Clin Psychopharmacol, 2005,20 ( 3 ) : 121 - 130.
  • 8CHUE P, DEVOS E, DUCHESNE I, et al. Hospitalization rates decrease during long-term treatment with long-acting risperidone injection[ J], Eur Neuropsychopharmacol, 2002,12 ( Suppl 3 ) : 281 -282.
  • 9EERDEKENS M,FLEISCHHACKER WW,YANG X, et al. Long-term safety of long-acting risperidone microspheres [J]. Eur Psychiatry,2002,17 ( Suppl 1 ) : 193.
  • 10KANE JM,EERDEKENS M,LINDENMAYER JP, et al. Long- acting injectable risperidonc: effcacy and safty of the first long- acting atypical antipsychotic [ J ]. AM J Psychiaty, 2003, 160 (6) :1125-1132.

共引文献26

同被引文献66

引证文献8

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部